5-alkyl-1,3-oxazole derivatives of 6-amino-nicotinic acids as alkyl ester bioisosteres are antagonists of the P2Y12 receptor

Future Medicinal Chemistry

Volumn 5, Issue 17, 2013, Pages 2037-2056

  Bach, Peter ^a   Boström, Jonas ^a   Brickmann, Kay ^a   Burgess, Laurence E ^a   Clarke, David ^a   Groneberg, Robert D ^a   Harvey, Darren M ^a   Laird, Ellen R ^a   O'Sullivan, Michael ^a   Zetterberg, Fredrik ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,4 OXADIAZOLE DERIVATIVE; 3 METHYL ISOXAZOLE; 5 METHYL DIHYDRO OXAZOLE; ALKYL GROUP; ANTITHROMBOCYTIC AGENT; CYTOCHROME P450; N (5 CHLOROTHIOPHEN 2 YLSULFONYL) 4 [3 CYANO 5 (5 ETHYL OXAZOL 2 YL) 6 METHYLPYRIDIN 2 YL]PIPERAZIN 1 CARBOXAMIDE; OXAZOLE DERIVATIVE; PURINERGIC P2Y RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

AB INITIO CALCULATION; ARTICLE; BINDING AFFINITY; DENSITY FUNCTIONAL THEORY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG POTENCY; HYDROGEN BOND; LIPOPHILICITY; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; STATIC ELECTRICITY; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; HUMANS; HYDROGEN BONDING; MICROSOMES; MODELS, MOLECULAR; OXAZOLES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84887945666     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.171     Document Type: Article

References (55)

1. Hollopeter G, Jantzen H-M, Vincent D et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409(6817), 202-207 (2001). (Pubitemid 32144286)
2. Abbracchio MP, Burnstock G, Boeynaems J-M et al. International union of pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol. Rev. 58(3), 281-341 (2006). (Pubitemid 44394905)
3. Mahaut-Smith M.P., Ennion SJ, Rolf M.G., Evans RJ ADP is not an agonist at P2X1 receptors: evidence for separate receptors stimulated by ATP and ADP on human platelets. Br. J. Pharmacol. 131(1), 108-114 (2000).
4. Storey R.F. Biology and pharmacology of the platelet P2Y12 receptor. Curr. Pharm. Design 12(10), 1255-1259 (2006). (Pubitemid 44082134)
5. Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nat. Rev. Drug Discov. 9(2), 154-169 (2010).
6. 12 receptor antagonists in development. Eur. Heart J. Suppl. 10(Suppl. I), I33-I37 (2008).
7. Savi P, Pereillo JM, Uzabiaga MF et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb. Haemost. 84, 891-896. (2000).
8. 12 receptor antagonist for the prevention of thrombosis. Bioorg. Med. Chem. Lett. 17(21), 6013-6018 (2007). (Pubitemid 47446193)
9. 12 antagonists. Semin. Thromb. Hemost. 31(2), 195-204 (2005). (Pubitemid 40605194)
10. 12 antagonists for inhibition of platelet aggregation. J. Med. Chem. 53(5), 2010-2037 (2010).
11. 12 antagonists for inhibition of platelet aggregation. Bioorg. Med. Chem. Lett. 20(4), 1388-1394 (2010).
12. 12 antagonists for inhibition of platelet aggregation. Bioorg. Med. Chem. Lett. 19(16), 4657-4663 (2009).
13. 12 antagonists for inhibition of platelet aggregation. Bioorg. Med. Chem. Lett. 19(21), 6148-6156 (2009).
14. 12 platelet aggregation inhibitors. Bioorg. Med. Chem. Lett. 19(20), 5919-5923 (2009).
15. 12 receptors. J. Med. Chem. 52(12), 3784-3793 (2009).
16. 12 receptor mediated platelet aggregation. Bioorg. Med. Chem. Lett. 18(6), 2167-2171 (2008). (Pubitemid 351380853)
17. 12 receptor. J. Med. Chem. 51(4), 1007-1025 (2008). (Pubitemid 351304709)
18. 12 receptor. Bioorg. Med. Chem. Lett. 21, 2877-2881 (2011).
19. Bach P, Boström J, Brickmann K et al. Synthesis, structure-property relationships and pharmacokinetic evaluation of ethyl 6-aminonicotinate sulfonylureas as antagonists of the P2Y12 receptor. Eur. J. Med. Chem. 65, 360-375 (2013).
20. 12 receptor. Separation in vivo of antithrombotic effect and bleeding for candidate drug AZD1283. J. Med. Chem. 56(17), 7015-7024(2013).
21. Meanwell NA. Synopsis of some recent tactical application of bioisosteres in drug design. J. Med. Chem. 54(8), 2529-2591 (2011).
22. Langdon SR, Ertl P, Brown N. Bioisosteric replacement and scaffold hopping in lead generation and optimization. Mol. Inf. 29(5), 366-385 (2010).
23. Lima LM, Barreiro EJ Bioisosterism: A useful strategy for molecular modification and drug design. Curr. Med. Chem. 12, 23-49 (2005). (Pubitemid 40089827)
24. Burger A. Medicinal Chemistry, 3rd Edition Wiley, NY, USA (1970).
25. Boström J., Grant JA, Fjellström O, Thelin A., Gustafsson D. Potent fibrinolysis inhibitor discovered by shape and electrostatic complementarity to the drug tranexamic acid. J. Med. Chem. 56(8), 3273-3280 (2013).
26. Silva NM, Tributino JLM, Miranda ALP, Barreiro EJ, Fraga CAM. New isoxazole derivatives designed as nicotinic acetylcholine receptor ligand candidates. Eur. J. Med. Chem. 37(2), 163-170 (2002). (Pubitemid 34164681)
27. Rice KD, Nuss JM An improved synthesis of 1,2,4-oxadiazoles on solid support. Bioorg. Med. Chem. Lett. 11(6), 753-755 (2001). (Pubitemid 32230672)
28. Butler RN. A study of the proton nuclear magnetic resonance spectra of aryl and monoand disubstituted N-methylazones. Can. J. Chem. 51, 2315-2322 (1973).
29. Wipf P, Miller CP A new synthesis of highly functionalized oxazoles. J. Org. Chem. 58(14), 3604-3606 (1993).
30. Von Geldern T.W., Hutchins C, Kester JA et al. Azole endothelin antagonists. 1. A receptor model explains an unusual structure-activity profile. J. Med. Chem. 39(4), 957-967 (1996). (Pubitemid 26067628)
31. Brown P, Davies DT, O'Hanlo PJ, Wilson JM The chemistry of pseudomonic acid (VIII). Part 15. Synthesis and antibacterial activity of a series of 5-alkyl, 5-alkenyl, and 5-heterosubstituted oxazoles. J. Med. Chem. 39(2), 446-457 (1996). (Pubitemid 26041457)
32. Kang F-A, Kodah J., Guan Q, Li X, Murray W V. Efficient conversion of Biginelli 3,4-dihydropyrimidin-2(1H)-one to pyrimidines via PyBrop-mediated coupling. J. Org. Chem. 70 (5), 1957-1960 (2005). (Pubitemid 40300171)
33. Gilson MK, Rashin A, Fine R., Honig B. On the calculation of electrostatic interactions in proteins. J. Mol. Biol. 184, 503-516 (1985). (Pubitemid 15013023)
34. 12 antagonists. Semin. Thromb. Hemost. 31(2), 195-204 (2005). (Pubitemid 40605194)
35. 12 independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J. Thromb. Haemost. 7(9), 1556-1565 (2009).
36. Regan SL, Maggs JL, Hammond T.G., Lambert C., Williams DP, Park BK Acyl glucuronides: the good, the bad and the ugly. Biopharm. Drug Dispos. 31(7), 367-395 (2010).
37. Sawamura R, Okudaira N, Watanabe K et al. Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide. Drug. Metab. Dispos. 38(10), 1857-1864 (2010).
38. Kim KS, Kimball SD, Misra RN et al. Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, x-ray crystallographic ana lysis, and biological activities. J. Med. Chem. 45(18), 3905-3927 (2002). (Pubitemid 35024294)
39. Dhanak D, Christmann LT, Darcy MG et al. Discovery of potent and selective phenylalanine derived CCR3 receptor antagonists. Part 2. Bioorg. Med. Chem. Lett. 11(11), 1445-1450 (2001). (Pubitemid 32510840)
40. Böhm H-J, Klebe, G, Brode S, Hesse U. Oxygen and nitrogen in competitive situations: which is the hydrogen-bond acceptor? Chem. Eur. J. 2, 1509-1513 (1996).
41. Kenny PW. Hydrogen bonding, electrostatic potential, and molecular design. J. Chem. Inf. Model. 49(5), 1234-1244 (2009).
42. Kenny PW. Prediction of hydrogen bond basicity from computed molecular electrostatic properties: implications for comparative molecular field ana lysis. J. Chem. Soc. Perkin. Trans. 2 (2), 199-202 (1994).
43. Murray JS, Ranganathan S, Politzer P. Correlations between the solvent hydrogen bond acceptor parameter b and the calculated molecular electrostatic potential. J. Org. Chem. 56(11), 3734-3737 (1991).
44. Orlek BS, Blaney FE, Brown F et al. Comparison of azabicyclic esters and oxadiazoles as ligands for the muscarinic receptor. J. Med. Chem. 34(9), 2726-2735 (1991).
45. Diana GD, Volkots DL, Nitz TJ et al. Oxadiazoles as ester bioisosteric replacements in compounds related to disoxaril. Antirhinovirus activity. J. Med. Chem. 37 (15), 2421-2436 (1994). (Pubitemid 24262332)
46. Wadsworth HJ, Jenkins SM, Orlek BS et al. Synthesis and muscarinic activities of quinuclidin-3-yltriazole and -tetrazole derivatives. J. Med. Chem. 35(7), 1280-1290 (1992).
47. Muchmore SW, Souers AJ, Akritopoulou-Zanze I. The use of three-dimensional shape and electrostatic similarity searching in the identification of a melanin-concentrating hormone receptor 1 antagonist. Chem. Biol. Drug Des. 67(2), 174-176 (2006). (Pubitemid 43881377)
48. Naylor E, Arredouani A, Vasudevan SR et al. Identification of a chemical probe for NAADP by virtual screening. Nat. Chem. Biol. 5, 220-226 (2009).
49. Waring MJ. Lipophilicity in drug discovery. Expert Opin. Drug Dis. 5, 235-248 (2010).
50. Deflorian F, Jacobsen KA Comparison of three GPCR structural templates for modeling of the P2Y12 nucloetide receptor. J. Comput. Aided Mol. Des. 25, 329-338 (2011).
51. Boström J., Hogner A, Schmitt S. Do structurally similar ligands bind in a similar fashion? J. Med. Chem. 49(23), 6716-6725 (2006). (Pubitemid 44749739)
52. Nobeli I, Price SL, Lommerse JPM, Taylor R. Hydrogen bonding properties of oxygen and nitrogen acceptors in aromatic heterocycles. J. Comput. Chem. 18(16), 2060-2074 (1997). (Pubitemid 127598558)
53. Laurence C, Brameld KA, Graton JRM, Le Questel J-Y, Renault E. The pKBHX Database. toward a better understanding of hydrogen-bond basicity for medicinal chemists. J. Med. Chem. 52(14), 4073-4086 (2009).
54. Churchill GC. Identification of a chemical probe for NAADP by virtual screening. Nat. Chem. Biol. 4, 220-226 (2009).
55. EON, ZAP and OE Chem Toolkits from OpenEye Scientific Software. www.eyesopen.com/toolkits